Orbus Therapeutics Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
M&A
- (Announced)
- Investors
-
6
Orbus Therapeutics General Information
Description
Operator of medicinal products designed to improve the health and quality of life for patients with rare diseases. The company's products are irreversible inhibitors of ornithine decarboxylase (ODC) that delay or freeze tumor growth by inhibiting the production of the enzyme, enabling medical professionals to prevent tumor growth in certain types of cancer.
Contact Information
Website
www.orbustherapeutics.comCorporate Office
- 3475 Edison Way
- Suite R
- Menlo Park, CA 94025
- United States
Corporate Office
- 3475 Edison Way
- Suite R
- Menlo Park, CA 94025
- United States
Orbus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 27-Oct-2026 | Announced | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series A) | 11-Aug-2020 | Completed | Clinical Trials - Phase 3 | |||
| 3. Later Stage VC (Series A3) | Completed | Clinical Trials - Phase 3 | ||||
| 2. Later Stage VC (Series A2) | 20-Mar-2019 | $18.5M | $51M | Completed | Clinical Trials - Phase 3 | |
| 1. Early Stage VC (Series A) | 19-Aug-2015 | $32.5M | $32.5M | Completed | Clinical Trials - Phase 3 |
Orbus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 26,452,884 | $0.010000 | $1.01 | $1.01 | 1x | $1.01 | 31.5% | |
| Series A | 21,428,577 | $0.010000 | $0.84 | $0.84 | 1x | $0.84 | 25.52% |
Orbus Therapeutics Comparisons
Industry
Financing
Details
Orbus Therapeutics Competitors (60)
One of Orbus Therapeutics’s 60 competitors is Enterome, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enterome | Venture Capital-Backed | Paris, France | ||||
| T3 Pharmaceuticals | Formerly VC-backed | Allschwil, Switzerland | ||||
| Adastra Pharmaceuticals | Formerly VC-backed | San Mateo, CA | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| PEP-Therapy | Venture Capital-Backed | Evry Cedex, France |
Orbus Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Orbus Therapeutics Patents
Orbus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026055332-A1 | Methods of treating astrocytoma | Pending | 05-Sep-2024 | ||
| US-12605349-B2 | Methods of treating grade 3 astrocytoma | Active | 05-Sep-2024 | ||
| US-20260060950-A1 | Methods of treating grade 3 astrocytoma | Active | 05-Sep-2024 | ||
| AU-2024223940-A1 | Compositions and methods of using eflornithine | Pending | 17-Feb-2023 | ||
| EP-4665325-A1 | Compositions and methods of using eflornithine | Pending | 17-Feb-2023 | A61K31/198 |
Orbus Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Orbus Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Agent Capital | Venture Capital | Minority | ||
| Adams Street Partners | PE/Buyout | Minority | ||
| Angel (individual) | Minority | |||
| H.I.G. HealthBridge Partners | Growth/Expansion | Minority |
Orbus Therapeutics FAQs
-
When was Orbus Therapeutics founded?
Orbus Therapeutics was founded in 2012.
-
Where is Orbus Therapeutics headquartered?
Orbus Therapeutics is headquartered in Menlo Park, CA.
-
What is the size of Orbus Therapeutics?
Orbus Therapeutics has 9 total employees.
-
What industry is Orbus Therapeutics in?
Orbus Therapeutics’s primary industry is Drug Discovery.
-
Is Orbus Therapeutics a private or public company?
Orbus Therapeutics is a Private company.
-
What is Orbus Therapeutics’s current revenue?
The current revenue for Orbus Therapeutics is .
-
How much funding has Orbus Therapeutics raised over time?
Orbus Therapeutics has raised $67M.
-
Who are Orbus Therapeutics’s investors?
Abingworth, Agent Capital, Adams Street Partners, , and H.I.G. HealthBridge Partners are 5 of 6 investors who have invested in Orbus Therapeutics.
-
Who are Orbus Therapeutics’s competitors?
Enterome, T3 Pharmaceuticals, Adastra Pharmaceuticals, Inovio Pharmaceuticals, and PEP-Therapy are some of the 60 competitors of Orbus Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
